Thyroid cancer is a very common endocrine system malignancy. Nevertheless, a dearth of precise markers makes it challenging to apply precision medicine to thyroid cancer. The limitations of standard diagnosis techniques (fine-needle aspiration biopsy), such as indeterminate cases and inaccuracies in distinguishing between different types of cancers, lead to unnecessary surgeries and thus warrant the development of more discriminatory biomarkers to improve the accuracy of existing diagnostic and prognostic techniques. Moreover, individualized therapies for thyroid cancer are necessary to avoid overtreatment of indolent lesions and undertreatment of high-risk progressive disease. As thyroid cancer metabolic signatures are associated with disease aggressiveness and responsiveness to therapy, metabolomics has been recently used for diagnostic and prognostic biomarker discovery. This strategy has enabled the detection of several metabolites from tissue samples or biofluids to facilitate the classification of disease aggressiveness and to potentially assist in individualized therapies. In this review, we summarize the utilization and potential of metabolomics in thyroid cancer.
甲状腺癌是一种极为常见的内分泌系统恶性肿瘤。然而，由于缺乏精确的生物标志物，精准医学在甲状腺癌领域的应用面临挑战。标准诊断技术（细针穿刺活检）存在局限性，例如无法确定病例性质及难以准确区分不同类型癌症，导致不必要的手术，因此需要开发更具鉴别力的生物标志物以提高现有诊断和预后技术的准确性。此外，为避免对惰性病变的过度治疗和对高风险进展性疾病治疗不足，甲状腺癌的个体化治疗显得尤为必要。由于甲状腺癌的代谢特征与疾病侵袭性及治疗反应性相关，代谢组学近年来被用于诊断和预后生物标志物的发现。该策略已实现从组织样本或生物体液中检测多种代谢物，有助于疾病侵袭性分类，并可能辅助个体化治疗。本文综述了代谢组学在甲状腺癌中的应用及其潜力。
Emerging Potential of Metabolomics in Thyroid Cancer—A Comprehensive Review
肿瘤(癌症)患者之家